Concerns about a potential link between long-term use of acid reflux medication and stomach cancer have persisted among patients and physicians alike. A new study, analyzing health data from Nordic countries, offers fresh evidence addressing those worries. Researchers found no increased risk of stomach cancer among individuals taking proton pump inhibitors (PPIs) for extended periods, providing valuable insight for both patients and healthcare providers managing conditions like GERD and peptic ulcers. The findings, published March 20 in the journal BMJ, may alleviate anxieties surrounding these commonly prescribed medications.
Updated March 26 | Published March 20
Long-term use of common medications for heartburn and ulcers does not increase the risk of stomach cancer, according to a new study analyzing health data from Nordic countries.
The research, published March 20 in the journal BMJ, offers reassurance to patients who rely on these medications for extended periods. Millions of people worldwide take proton pump inhibitors (PPIs) to manage conditions like gastroesophageal reflux disease (GERD) and peptic ulcers, and concerns about potential long-term side effects have been ongoing.
Researchers matched cancer patients with healthy individuals, tracked PPI use, and accounted for factors like age, smoking habits, and obesity. Their analysis revealed no link between the medications and the development of stomach cancer.
“This finding should be a relief for patients who require long-term treatment with proton pump inhibitors and is valuable for healthcare when making clinical decisions,” researchers stated in a press release. The study involved researchers from institutions including the Karolinska Institute.
